Study examines a novel way to bring addiction care and HIV prevention to people who inject drugs
Researchers from the HIV Prevention Trials Network (HPTN) have presented results from the HPTN 094 ("INTEGRA") study at the ...
Reformulation of HIV prevention drug lenacapavir makes it last for a year
A team of pharmaceutical researchers at biopharma company Gilead Sciences has announced that a reformulation of its HIV prevention drug lenacapavir allows it to persist in the body for up to a year.
GSK, Pfizer's ViiV Healthcare Shows Strong HIV Viral Suppression In Latest Study
ViiV Healthcare's EMBRACE study shows VH109 with CAB LA effectively suppresses HIV. The company also reports promising early ...
1GSK, PFE : GSK, Pfizer's ViiV Healthcare Shows Strong HIV Viral Suppression In...
ViiV Healthcare's EMBRACE study shows VH109 with CAB LA effectively suppresses HIV. The company also reports promising early ...
BioSpace11h
Gilead, GSK-ViiV Move Ahead With Long-Acting HIV Options Following Early-Stage Readouts
Gilead plans to go straight to Phase III studies for once-yearly lenacapavir, while GSK and Viiv will push forward with their ...
Infectious Disease Advisor10h
Hepatitis C Rates in HIV More Than Doubled for Some Risk Groups From 1995 to 2023
Incident HCV infection more than doubled among HIV-positive MSM with no history of injection drug use between 1995 and 2023.
Healio3h
42-year HIV survivor tells CROI she has gone ‘from fear to courage’
During the opening day of the Conference on Retroviruses and Opportunistic Infections, Rebecca Denison, a decades-long HIV ...
“Magic” for Those Who Can’t Take Pills: Groundbreaking HIV Treatment Achieves 98% Viral Suppression
UCSF researchers are the first to confirm that this approach is effective for the patients who need it most. Patients who ...
Infectious Disease Advisor10h
Severe Mpox, Long-Term Sequelae More Likely in Patients With Uncontrolled HIV
Severe mpox and long-term sequelae such as severe scarring were more likely to occur among HIV-positive patients with detectable viral loads and low CD4 counts.
Why Climbers on Aconcagua Get Serious Altitude Illness
New data identifies two key risk factors for high-altitude pulmonary edema, a leading cause of death on the mountain.
KFF Health News11h
Gilead’s HIV Drug Prevents Infection With One Shot A Year Instead Of Two
The company is planning a Phase 3 trial for the new formulation of lenacapavir, Stat reports. Other pharma and technology news is on microplastics and the spread of antibiotic-resistant superbugs; a ...